Nuvectra Corporation announced the appointment of Ben Tranchina as Chief Technology Officer (CTO), effective August 24, 2018. Mr. Tranchina has over 25 years of industry experience and most relevantly served as VP, Product Development at St. Jude Medical, where he led the development of the company’s neuromodulation portfolio, following his time at Advanced Neuromodulation Systems Inc. Mr. Tranchina will replace the company’s current CTO, Dr. Norbert Kaula, who announced his intention to resign to pursue other interests, effective August 17, 2018. Ben Tranchina has more than 25 years of experience in technology business leadership for early-stage and multi-national commercial companies, and approximately 30 issued or pending patents relevant to neuromodulation. Most importantly, Mr. Tranchina served in various leadership roles for nine years at Advanced Neuromodulation Systems Inc. and St. Jude Medical, where he led the development of nine first-to-market products. Most recently, Mr. Tranchina was the Chief Technology Officer of Neurotechnology Innovations Translator (NIT), LLC, a privately held company which develops and commercializes neurotechnology solutions. During his tenure at NIT, he also served as CEO for NIT portfolio company, Veressa Medical, where he led development of an innovative peripheral nerve stimulation system for the treatment of pelvic floor dysfunction and peripheral pain.